Paul Edwards Posted April 3, 2014 Share Posted April 3, 2014 In addition to the current clinical trials for Enzalutamide and Xofigo previously mentioned in this forum, a Phase III trial, A Study of ARN-509 in Men With Non-Metastatic Castration Resistant Prostate Cancer (SPARTAN), is currently recruiting. ARN-509 is a new second-generation anti-androgen that binds directly to the ligand-binding domain of the androgen receptor, impairing nuclear translocation and DNA binding. Earlier trials in mice suggested that it may possibly be more efficacious than Enzalutamide. There is only one Australian site for the trial at Darlinghurst NSW. Click this link for more details of this trial. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.